Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Lung Non-Small Cell Carcinoma: early-phase trial registry
8 of 15 indexed Advanced Lung Non-Small Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 8 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Advanced Lung Non-Small Cell Carcinoma: 15 US clinical trials tracked, 8 recruiting.
Advanced Lung Non-Small Cell Carcinoma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition advanced-lung-non-small-cell-carcinoma
OPEN 8 | RECR 53% | LATE 1 | EARLY 13 | RANK #1140 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Beta-Thalassemia (53% recruiting · 15 trials)
Advanced Lung Non-Small Cell Carcinoma lists 8 open slots (53% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Lung Non-Small Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Lung Non-Small Cell Carcinoma is recruiting above its size-band peers.
8 of 15 indexed trials (53.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Lung Non-Small Cell Carcinoma research.
National Cancer Institute (NCI) accounts for 5 of 15 trials (33.3%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Advanced Lung Non-Small Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 15 trials that report a genuine target (sentinel values excluded). 12 of those (80%) plan for fewer than 100 participants.
-
Advanced Lung Non-Small Cell Carcinoma research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
University of Rochester
NCT06073431
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
National Cancer Institute (NCI)
NCT06096844
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
University of California, Davis
NCT05967533
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
Emory University
NCT04762199
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
National Cancer Institute (NCI)
NCT03191149
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
NCT07017829
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
NCT06731270
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
City of Hope Medical Center
NCT06249282
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05096663
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
NCT04491942
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
NCT02983578
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03831932
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
City of Hope Medical Center
NCT05166616
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
NCT04514484
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
University of California, Irvine
NCT05334329
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Lung Non-Small Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Lung Non-Small Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Lung Non-Small Cell Carcinoma page
15 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Advanced Lung Non-Small Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Advanced Lung Non-Small Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Lung Non-Small Cell Carcinoma condition card totals 15 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.